Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ZLAB
ZLAB logo

ZLAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
19.035
Open
18.610
VWAP
18.78
Vol
264.31K
Mkt Cap
2.11B
Low
18.440
Amount
4.96M
EV/EBITDA(TTM)
--
Total Shares
110.64M
EV
1.67B
EV/OCF(TTM)
--
P/S(TTM)
4.58
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Show More

Events Timeline

(ET)
2026-02-26
08:00:00
Zai Lab Reports Q4 Revenue of $127.6M
select
2026-01-06 (ET)
2026-01-06
07:40:00
Zai Lab Receives Approval for Augtryo to Treat Adult Solid Tumors
select
2025-12-24 (ET)
2025-12-24
10:10:00
Zai Lab Shares Rise 7.4% to $18.77
select
2025-12-23 (ET)
2025-12-23
09:10:00
U.S. Economic Growth Exceeds Expectations, Stock Futures Edge Lower
select
2025-12-23
07:50:00
Zai Lab Receives China's Approval for Cobenfy to Treat Schizophrenia in Adults
select

News

seekingalpha
9.5
02-26seekingalpha
Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress
  • Significant Revenue Growth: Zai Lab reported total revenue of $127.6 million in Q4 2025, a 17% year-over-year increase, with full-year revenue reaching $460.2 million, up 15%, demonstrating strong performance driven by contributions from XACDURO and NUZYRA.
  • Rapid R&D Progress: Zoci showed an 80% objective response rate in untreated brain metastases patients with a favorable safety profile, with management emphasizing its advancement to global Phase III trials within two years, targeting U.S. approval by 2028, marking a significant breakthrough in oncology.
  • Strategic Transition Year: Management views 2026 as a transition year focused on execution and upcoming launches, and while full-year financial guidance was not provided, the expectation is to leverage a robust pipeline and strong cash position to drive long-term growth, reflecting confidence in future market opportunities.
  • Effective Cost Control: R&D expenses declined by 6% for the full year, while SG&A expenses decreased by 12% in Q4, leading to a 19% improvement in operating loss to $229.4 million, showcasing the company's success in enhancing operational leverage and financial flexibility, strengthening its position in a competitive market.
seekingalpha
9.5
02-25seekingalpha
Zai Lab Scheduled to Announce Q4 Earnings on February 26
  • Earnings Announcement Date: Zai Lab (ZLAB) is set to announce its Q4 2023 earnings on February 26 before market open, drawing increased attention from investors amid a competitive biopharmaceutical landscape.
  • Earnings Expectations: The consensus EPS estimate stands at -$0.42, reflecting a 47.5% year-over-year improvement, indicating some progress in the company's efforts to enhance profitability despite remaining in the red.
  • Revenue Expectations: The consensus revenue estimate is $122.67 million, representing a 12.4% year-over-year increase, highlighting Zai Lab's potential for sales growth as market demand recovers.
  • Estimate Revisions: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have faced five downward revisions with no upward changes, suggesting analysts' cautious outlook on the company's future performance.
moomoo
4.0
02-20moomoo
ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53
  • Company Announcement: Zailab Ltd. has announced a reduction in its target price.
  • New Target Price: The target price has been cut from $58 to $53.
PRnewswire
8.5
02-05PRnewswire
Oncolytics Biotech Receives FDA Fast Track Designation
  • FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer, which is expected to expedite the approval process and enhance market competitiveness.
  • Clinical Data Advantage: The 33% response rate of pelareorep combined with standard chemotherapy significantly surpasses the 10% rate of chemotherapy alone, with a median survival of 27 months, indicating its potential value in hard-to-treat cancer populations.
  • Significant Market Opportunity: The annual revenue for second-line treatment of KRAS-mutant colorectal cancer ranges between $3 billion and $5 billion, positioning Oncolytics' innovative therapy to capture a substantial share in this rapidly growing market.
  • Team Expansion and Strategic Positioning: Oncolytics Biotech has recently appointed two executives to support its expansion plans, demonstrating the company's commitment to future clinical trials and market outreach, thereby strengthening its leadership position in the biotech sector.
Newsfilter
8.5
02-05Newsfilter
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
  • Regulatory Acceleration: In 2025, the FDA approved over 50 oncology drugs, with a notable shift towards targeted therapies for high-unmet-need solid tumors in 2026, projecting a market opportunity of $326.82 billion by 2031, indicating robust commercial potential.
  • Fast Track Designation: Oncolytics Biotech's pelareorep received FDA Fast Track Designation for KRAS-mutant colorectal cancer, showing a 33% response rate when combined with standard chemotherapy, significantly higher than the 10% with chemotherapy alone, which will expedite its approval process.
  • Clinical Trial Plans: Oncolytics plans to launch a controlled study comparing pelareorep with standard care in March 2026, with interim data expected by year-end, providing crucial clinical evidence in a competitive market.
  • Team Expansion: Oncolytics Biotech recently appointed two key executives to enhance its strategic and operational capabilities, supporting its expanding R&D projects, reflecting the company's confidence and preparedness for future growth.
seekingalpha
6.5
02-04seekingalpha
ClearBridge International Growth Strategy Underperforms in Q4 2025
  • Quarterly Performance Review: The ClearBridge International Growth Strategy underperformed its primary MSCI EAFE benchmark in Q4 2025, indicating vulnerability in the portfolio amidst market fluctuations, which may affect investor confidence.
  • Portfolio Adjustments: The strategy exited positions in Zai Lab, UniCredit, and Linde during the quarter while repurchasing EssilorLuxottica, Galderma Group, and Ryanair, demonstrating management's sensitivity to market dynamics and adaptability.
  • New and Closed Positions: The fund initiated positions in Sandvik and Mettler-Toledo while closing several positions including Mitsubishi Heavy Industries, Givaudan, and Lenovo, reflecting a reassessment of future market opportunities.
  • Sales Dynamics: Trane Technologies was among the larger sales in the portfolio, potentially indicating a cautious outlook on the company's future growth prospects, thereby influencing the overall direction of the investment strategy.
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
Wall Street analysts forecast ZLAB stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
25.70
Averages
47.93
High
74.00
Current: 0.000
sliders
Low
25.70
Averages
47.93
High
74.00
Cantor Fitzgerald
Overweight
downgrade
$55 -> $37
AI Analysis
2026-02-27
Reason
Cantor Fitzgerald
Price Target
$55 -> $37
AI Analysis
2026-02-27
downgrade
Overweight
Reason
Cantor Fitzgerald lowered the firm's price target on Zai Lab to $37 from $55 and keeps an Overweight rating on the shares. Zai Lab reported Q4 and full-year revenues of $127.6M and $460.2M, respectively, in line with consensus, though Vyvgart sales were slightly weaker than expected, the analyst tells investors in a research note. Management indicated that 2026 top-line growth is likely to be modest, with volume gains offset by pricing pressures and competition in China, the firm says.
Citi
Yigal Nochomovitz
Buy
downgrade
$53 -> $47
2026-02-27
Reason
Citi
Yigal Nochomovitz
Price Target
$53 -> $47
2026-02-27
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Zai Lab to $47 from $53 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ZLAB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is -18.08, compared to its 5-year average forward P/E of -18.03. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.03
Current PE
-18.08
Overvalued PE
2.92
Undervalued PE
-38.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.26
Current EV/EBITDA
-27.61
Overvalued EV/EBITDA
-0.04
Undervalued EV/EBITDA
-28.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.04
Current PS
3.52
Overvalued PS
37.54
Undervalued PS
-3.46

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock should I trade today
Intellectia · 19 candidates
Market Cap: >= 1000.00MPrice: $5.00 - $100.00Price Change Pct: >= $3.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
FORM logo
FORM
FormFactor Inc
5.43B
AXTI logo
AXTI
AXT Inc
1.11B
OCUL logo
OCUL
Ocular Therapeutix Inc
1.80B
BLBD logo
BLBD
Blue Bird Corp
1.58B
KLIC logo
KLIC
Kulicke and Soffa Industries Inc
2.89B

Whales Holding ZLAB

F
Frazier Life Sciences Management, LP
Holding
ZLAB
+8.24%
3M Return
R
Rock Springs Capital Management LP
Holding
ZLAB
-7.73%
3M Return
Q
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
Holding
ZLAB
-12.15%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 18.87 USD — it has decreased -1.05

What is Zai Lab Ltd (ZLAB)'s business?

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 127.60M USD, increased 16.99

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -37.50

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1784 emplpoyees as of March 12 2026.

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 2.11B USD.